thanks for the news release Paul. I note that it also states in the second paragraph:

[quote]Combined with chemotherapy, Erbitux extended the lives of those receiving the treatment combination compared with those receiving chemotherapy alone. Erbitux already is FDA-approved for certain types of colon cancer, and has been approved since 2006 for treatment of non-metastatic head and neck cancer in combination with radiation therapy (first-line) or as a single agent (following standard treatment).[/quote]

thanks for finding the date that it was FDA approved as 1st line therapy in conjunction with radiation which preceded the extended indication mentioned in the press release.